Analysis of biomarkers to predict response to pembrolizumab are ongoing.
The TC model uses various parameters to predict risk such as genetic risk and nonfamilial factors including personal, hormonal, and lifestyle characteristics.
Overall survival data are not currently mature. However, at the time of this analysis no difference in overall survival was observed between the 3 treatment arms.
A longer treatment-free survival interval associated with surgery may contribute to overall survival.
The researchers found that patients who received pelvic radiation had a decreased chance of live birth.
This study evaluated the combination of bevacizumab with an antibody drug conjugate targeted to the folate receptor alpha in the setting of epithelial ovarian cancer.